RxDoctor Payments Data

Samuel Franklin, MD

Internal Medicine · Louisville, GANPI 1245590793

Payments from drug & device makers

$1,445in general payments, 2019–2025

Across 89 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$492
  • Novo Nordisk$212
  • Bayer$117
  • Boehringer Ingelheim$102
  • Novartis$84
  • Amgen$63
  • plus $375 from 13 others

What the payments were for

  • Food & beverage$1,439100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,445 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$3,163
Medicare patients
26
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban467$171,950
JardianceEmpagliflozin147$140,083
OzempicSemaglutide41$57,225
Dupixent PenDupilumab12$51,318
FarxigaDapagliflozin Propanediol49$47,713
TrulicityDulaglutide39$47,074
RybelsusSemaglutide31$37,418
JanuviaSitagliptin Phosphate69$34,148
MounjaroTirzepatide18$29,111
TradjentaLinagliptin119$27,233
RexultiBrexpiprazole32$19,694
JanumetSitagliptin Phos/Metformin Hcl19$19,252
EntrestoSacubitril/Valsartan53$18,703
XareltoRivaroxaban21$15,470
Risperdal ConstaRisperidone Microspheres28$15,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$102$178,136287 claims
PfizerEliquis$55$171,950467 claims
Novo NordiskOzempic, Rybelsus$212$94,64272 claims
Lilly USA, LLCTrulicity, Mounjaro$36$76,18657 claims
AstraZenecaFarxiga, Breztri Aerosphere, Lokelma, Symbicort$492$72,025105 claims
MerckJanuvia, Janumet$35$53,39988 claims
GSKBreo Ellipta, Trelegy Ellipta$16$19,45434 claims
NovartisEntresto$84$18,70353 claims
AbbVieLinzess$33$10,56616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Louisville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →